Natera, Inc. Stock

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-06-10 pm EDT 5-day change 1st Jan Change
111.7 USD +0.42% Intraday chart for Natera, Inc. +3.09% +78.26%
Sales 2024 * 1.43B Sales 2025 * 1.68B Capitalization 13.65B
Net income 2024 * -298M Net income 2025 * -139M EV / Sales 2024 * 9.2 x
Net cash position 2024 * 472M Net cash position 2025 * 520M EV / Sales 2025 * 7.82 x
P/E ratio 2024 *
-45.1 x
P/E ratio 2025 *
-95.4 x
Employees 3,288
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.42%
1 week+3.09%
Current month+4.82%
1 month+6.05%
3 months+25.07%
6 months+96.93%
Current year+78.26%
More quotes
1 week
104.79
Extreme 104.785
112.72
1 month
102.00
Extreme 102
112.72
Current year
58.53
Extreme 58.53
112.72
1 year
36.90
Extreme 36.9
112.72
3 years
26.10
Extreme 26.1
129.09
5 years
16.87
Extreme 16.87
129.09
10 years
6.52
Extreme 6.52
129.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 10-11-30
Founder 51 03-10-31
Founder 51 03-10-31
Members of the board TitleAgeSince
Director/Board Member 59 14-10-31
Director/Board Member 50 06-12-31
Director/Board Member 76 14-01-31
More insiders
Date Price Change Volume
24-06-10 111.7 +0.42% 1,351,659
24-06-07 111.2 +1.80% 906,775
24-06-06 109.2 -1.42% 691,903
24-06-05 110.8 +4.58% 1,069,440
24-06-04 105.9 -2.19% 848,191

Delayed Quote Nasdaq, June 10, 2024 at 04:00 pm EDT

More quotes
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
111.2 USD
Average target price
123.5 USD
Spread / Average Target
+11.07%
Consensus